Inhibition of P-glycoprotein-mediated transport by S-adenosylmethionine and cynarin in multidrug-resistant human uterine sarcoma MES-SA/Dx5 cells

Journal of Biological Regulators and Homeostatic Agents

Volumn 26, Issue 3, 2012, Pages 495-504

  Angelini, Antonio ^a   Di Pietro, R ^a   Centurione, L ^a   Castellani, M L ^a   Conti, P ^a   Porreca, E ^a   Cuccurullo, F ^a   Di Ilio, C ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Cynarin; Doxo; MES SA Dx5; P glycoprotein; S adenosylmethionine

Indexed keywords

CATALASE; CYNARINE; DOXORUBICIN; GLUTATHIONE; MULTIDRUG RESISTANCE PROTEIN; REACTIVE OXYGEN METABOLITE; S ADENOSYLMETHIONINE;

ARTICLE; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE; SARCOMA CELL; UTERUS SARCOMA;

ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CHOLAGOGUES AND CHOLERETICS; CINNAMATES; DOXORUBICIN; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; S-ADENOSYLMETHIONINE; SARCOMA; UTERINE NEOPLASMS;

EID: 84868137125     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Ling V. Multidrug resistance: molecular mechanism and clinical relevance. Cancer Chemother Pharmacol 1997; 40:3-8.
2. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455:152-62.
3. Pastan I, Gottesman MM. Multiple-drug resistance in human cancer. N Engl J Med 1987; 316:1388-93. (Pubitemid 17079683)
4. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62:385-427. (Pubitemid 23237876)
5. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1991; 39:361-98.
6. Nooter K, Stoter G: Molecular mechanism of multidrug resistance in cancer chemotherapy. Pathol Res Pract 1996; 192:768-80. (Pubitemid 26302251)
7. Seeber S, Asieka R, Schmidt CG, Achterrath W, Crooke GT. In vivo resistance towards anthracycline, etoposide and cisdiaminedichloroplatinum. Cancer Res 1982; 42:4719-25. (Pubitemid 13205979)
8. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53:615-27. (Pubitemid 34177898)
9. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48-58. (Pubitemid 37328807)
10. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80:2735-9.
11. Endicott JA, and Ling VZ. The biochemistry of P-glycoprotein mediated multidrug resistance. Annu Rev Biochem 1989; 58:137-71. (Pubitemid 19172967)
12. Higgins CF. ABC transporters: from microorganism to man. Annu Rev Cell Biol 1992; 8:67-113.
13. Sauna ZE, Smith MM, Muller M, Kerr KM and Ambudkar SV: The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 2001; 33:481-91. (Pubitemid 34052574)
14. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11:265-83.
15. Borowski E, Bontemps-Gracz MM, Piwkowska A. Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells. Acta Biochim Pol 2005; 52:609-27. (Pubitemid 41571706)
16. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 2003; 10:159-65. (Pubitemid 36437822)
17. Sarkadi B, Müller M. Search for specific inhibitors of multidrug resistance in cancer. Semin Cancer Biol 1997; 8:171-82. (Pubitemid 28041014)
18. Twentymann PR, Bleehen NM. Resistance modification by PSC 833, a novel non-immunosuppressive cyclosporine. Eur J Cancer 1991; 7:1639-42.
19. Green LJ, Marder P, Slapack CA. Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells. Biochem Pharmacol 2001; 61:1393-9. (Pubitemid 32452355)
20. Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Shellens JH, van Tellingen O. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res 2000; 6:4416-21.
21. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997; 40:13-19.
22. Angelini A, Di Ilio C, Castellani ML, Conti P, Cuccurullo F. Modulation of multidrug resistance P-glycoprotein activity by flavonoids and honokiol in human doxorubicin-resistant sarcoma cells (MES-SA/Dx5): implications for natural sedatives as chemosensitizing agents in cancer therapy. J Biol Regul Homeost Agents 2010; 24:197-205.
23. Mato JM, Lu SC. Role of S-Adenosyl-L-Metionine in liver health and injury. Hepatology 2007; 45:1306-12. (Pubitemid 46775795)
24. Martinez-Chantar ML, Garcia-Trevijano ER, Latasa MU, Mato IP, Del Pino MS, Corrales FJ, Avila MA, Mato JM. Importance of a deficiency in S-adenosyl-L-methionine synthesis in the pathogenesis of liver injury. Am J Clin Nutr 2002; 76:1177-82.
25. Vincenzi B, Daniele S, Frezza AM, Berti P, Vespasiani, Picardi A, Tonini G. The role of S-adenosilymethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectalcancer patients treated with bevacizumab plus oxaliplatin-based regimen. Support Care Cancer 2012; 20:135-9.
26. Santini D, Vincenzi B, Massacesi C, et al. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. Anticancer Res 2003; 23:5173-9. (Pubitemid 38182142)
27. Vincenzi B, Santini D, Frezza AM, Berti P, Vespasiani U, Picardi A, Tonini G. The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen. Exp Opin Drug Saf 2011; 10:345-49.
28. Gebhardt R, Fausel M. Antioxidant and hepatoprotective effects of artichoke extracts and constituents in cultured rat hepatocytes. Toxicology in Vitro 1997; 11:669-72. (Pubitemid 27512717)
29. Mehmetcik G, Ozdemirler G, Kocak-Toker N, Cevikbas U, Uysal M. Effect of pre-treatment with artichoke extract on carbon tetrachloride-induced liver injury and oxidative stress. Exp Toxicol Pathol 2008; 60:475-80.
30. Wesolowska O, Paprocka M, Koziak J, Motohashi N, Dus D, Michalak K. Human sarcoma cell lines MES-SA and MES-SA/Dx5 as a model for multidrug resistance modulators screening. Anticancer Res 2005; 25:383-9. (Pubitemid 40470134)
31. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 2005; 41(5):1967-72.
32. Mosmann TJ. rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Methods 1983; 65:55-63.
33. Ellman GC. Tissue sulfhydrylic groups. Arch Biochem Biophys 1959, 82:70-77.
34. Jakubowski W, Bartosz G: 2,7-dichlorofluoresceinoxidation and reactive oxygen species: what does it measure. Cell Biol Int 2000; 24:757-60.
35. Beers RF, Sizer IW. A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. Bio Chem 1952; 195:133-40.
36. Mato JM, Corrales FJ, Lu SC, Avila MA. S-Adenosylmethionine: a control switch that regulates liver function. FASEB 2002; 16:15-26. (Pubitemid 34027946)